Fosun Pharmaceutical
PulseAugur coverage of Fosun Pharmaceutical — every cluster mentioning Fosun Pharmaceutical across labs, papers, and developer communities, ranked by signal.
1 day(s) with sentiment data
Fosun Pharma expanding oncology and liver disease pipelines
Fosun Pharma recently secured NMPA approval for a breast cancer drug and simultaneously invested significantly in a liver disease drug developer. This dual focus indicates a strategic expansion of their pipeline in both oncology and liver disease therapeutic areas, potentially leveraging China's supportive regulatory environment for domestic innovation.
Fosun Pharma to pursue further M&A for pipeline expansion
Following the recent investment in Xingyao Kunze and the approval of its breast cancer drug, Fosun Pharma may continue to pursue mergers and acquisitions or strategic investments to bolster its drug pipeline. The company's proactive approach suggests a strategy to capitalize on China's growing biotech sector and regulatory tailwinds.
Fosun Pharma benefiting from China's domestic drug approval surge
The recent approval of Fosun Pharma's breast cancer drug aligns with a broader trend of China's NMPA approving a high volume of domestic innovative medicines. This suggests Fosun Pharma is effectively navigating and benefiting from the streamlined regulatory processes and increased R&D investment within China's burgeoning biotech ecosystem.
-
Fosun Pharma subsidiary gets nod for Parkinson's drug trial
Fosun Pharmaceutical has announced that its subsidiary, Fosun Wanbang, has received approval from the National Medical Products Administration to conduct clinical trials for DM1001, a treatment for idiopathic Parkinson'…
-
Fosun Pharma Establishes New 75M RMB Healthcare Investment Partnership
Fosun Pharma, through its investment arm Suzhou Junming Zhiyuan Venture Capital, has co-established a new investment partnership in Jinan with an initial capital of 75.01 million RMB. The partnership, named Jinan Xing W…
-
Fosun Pharma subsidiary's breast cancer drug approved in China
Fosun Pharma announced that its subsidiary, Shanghai Fosun Pharmaceutical Biotechnology Co., Ltd., has received approval from China's National Medical Products Administration for its Pertuzumab Injection. This approval …
-
China's drug regulator approves wave of domestic innovative medicines
China's National Medical Products Administration (NMPA) has approved a significant number of domestically developed innovative medicines, with 15 out of 19 cleared this year originating from Chinese companies. This surg…
-
Fosun Pharma invests 414M yuan in liver disease drug developer Xingyao Kunze
Fosun Pharma is investing 414 million yuan in a Series B funding round for Xingyao Kunze, a company focused on innovative liver disease drugs. This investment, which includes acquiring shares from existing shareholders,…
-
Fosun Pharma invests 414M yuan in liver disease drug developer Starry Kunze
Fosun Pharma's subsidiary, Fosun Pharma Industry, is investing 414 million yuan in Starry Kunze's Series B funding round. This investment includes subscribing to new capital and acquiring existing shares, which will res…
-
Titan Co. stock surges amid R&D clarification; Fosun Pharma drug gains EU approval
Titan Co. announced its stock price experienced abnormal fluctuations, with a cumulative increase exceeding 20% over three trading days. The company clarified that its high-end electronic fabric jet looms are still in t…
-
Fosun Pharma subsidiary gains EU approval for two new cancer drug indications
Fosun Pharma announced that its subsidiary, Shanghai Henlius Biotech, has received European Commission approval for two new indications for its drug, Serplulimab Injection (Hetronifly®). These approvals cover the first-…